Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
Improving supportive care of young patients with breast cancer
According to Prof. Ann Partridge, 2024 ESMO Awardee, young patients with breast cancer have unique needs that must be addressed to achieve better outcomes
Translational research: from bytes to bedside
According to Prof. Serena Nik-Zainal, 2024 ESMO Translational Research Awardee it is important to change the mindset of the cancer community to embrace all the information available through genome research
Role of female leaders in addressing gender gaps in oncology
ESMO Women for Oncology Award Recipient Prof. Myung-Ju Ahn discusses gender equity in lung cancer research
Melanoma research continues to lead the way in new immunotherapies
For recipient of the ESMO Lifetime Achievement Award, Prof. John Haanen, melanoma research has provided him with a career full of innovation, but there is always more to explore
Is gender equity still an issue in oncology?
At the ESMO Congress 2024, the ESMO Women for Oncology (W4O) Committee is presenting new findings on female representation in leadership positions
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
Cancer Control Principles
How to mark a tangible impact in cancer control
Recent research shows that tailored strategies and political commitment can revert current epidemiology trends of cancer
First gene engineered T-cell therapy for solid tumours confirmed to be a promising tool
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval